The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares | MicrobiomeTrials← Back to trialsNCT07143188
The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-09Est. Completion: 2027-01
Enrollment target: 42 participants Locations- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Other microbiome trials you might be interested in
DysphagiaEosinophilic Esophagitis
Background:
Eosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the…
Bethesda, United StatesEst. completion Aug 31, 2027
Autoimmune Diseases of the Nervous SystemNeuromyelitis Optica Spectrum DisorderMultiple SclerosisGuillain-Barre SyndromeAcute Disseminated EncephalomyelitisAutoimmune EncephalitisStiff-Person SyndromeMyasthenia Gravis
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Idiopathic Inflammatory Myopathies
Autoimmune Diseases
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the ne…
Wuhan, ChinaEst. completion Jul 2027
Crohn Disease
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Dothan, United StatesEst. completion Jul 4, 2023